Gilead’s $4.3B Bet on CymaBay’s Liver Drug

Gilead Sciences plans to acquire CymaBay Therapeutics for $4.3 billion, expanding their liver disease portfolio. The deal is expected to be completed in Q1 2024 and brings the potential treatment seladelpar for primary biliary cholangitis. This move is predicted to have a neutral impact on earnings per share in 2025 but could drive future growth. Gilead's strong financial position and commitment to shareholder value make this acquisition promising.